A key European regulatory committee backed Bluebird’s gene therapy to treat transfusion-dependent β-thalassemia, Zynteglo, setting up a possible EU approval in the second quarter—and renewing ongoing speculation about how the one-time treatment will be priced. More: Bluebird tees up its
read moreIf approved, the drug will be the only therapy in nearly 20 years to reduce the risk of end-stage kidney disease. More: J&J submits sNDA for Invokana after premature end to clinical trial Source: News
read moreThe study found that patients warned of adverse consequences to their own health of skipping doses were more likely to adhere. More: Boots tests ‘behavioural nudge theory’ for medication adherence Source: News
read moreThe CE-marked prognostic test for guiding treatment options uses a gene expression “signature”. More: NICE backs PredictImmune's IBD prognosis test Source: News
read moreThe partnership will give the American pharma giant access to Concerto’s eurekaHealth AI insights platform. More: BMS signs deal with Concerto HealthAI Source: News
read moreThe collaboration is aligned with AstraZeneca’s science-led strategy in oncology. More: AstraZeneca and Daiichi sign .9bn cancer drug deal Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals